Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Item No. 24769

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Pituitary adenylate cyclase-activating peptide (PACAP) (1-27) is a PACAP receptor agonist with IC50 values of 3, 2, and 5 nM, respectively, for rat PAC1, rat VPAC1, and human VPAC2 recombinant receptors expressed in CHO cells.1 It binds to PACAP receptors in rat brain membrane (IC50 = 9.55 nM) and to SH-SY5Y and SK-N-MC human neuroblastoma and T47D human breast cancer cells (IC50s = 1.1, 1.9, and 0.9 nM, respectively).2,3 PACAP (1-27) stimulates cAMP accumulation in H-SY5Y, SK-N-MC, and T47D cells (EC50s = 0.19, 0.22, and 0.17 nM, respectively).3 In vivo, in newborn pigs, PACAP (1-27) (1 μM) induces vasodilation of pial arterioles by 36%.4
WARNING This product is not for human or veterinary use.
1. Fragments of pituitary adenylate cyclase activating polypeptide discriminate between type I and II recombinant receptors. Eur. J. Pharmacol. 287(1), 7-11 (1995).
2. Functional characterization of structural alterations in the sequence of the vasodilatory peptide maxadilan yields a pituitary adenylate cyclase-
3. Maxadilan interacts with receptors for pituitary adenylyl cyclase activating peptide in human SH-
4. Pituitary adenylate cyclase-